Modular Integrase (MINT) Platform

Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.

The MINT platform does not use CRISPR, zinc fingers, or TALEs to target DNA. Instead, we successfully reprogrammed the specificity of the Serine Integrase Bxb1, directing it to clinically relevant sites in the human genome without needing to first create a “landing pad” sequence containing the natural bacterial DNA sequence.

Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Modular Integrase (MINT) Platform

Site-Directed Integration of Large DNA Sequences into Endogenous Sites in the Human Genome using an engineered MINT Platform